不同剂量双歧杆菌乳杆菌三联活菌片联合乳果糖治疗功能性便秘的效果比较

Comparison of effects of different doses of bifidobacterium-lactobacillus triple viable tablets combined with lactulose in treatment of functional constipation

目的:探讨不同剂量双歧杆菌乳杆菌三联活菌片联合乳果糖治疗功能性便秘的效果。方法:选择某院功能性便秘患者90例,随机分为治疗1组、治疗2组以及对照组,每组各30例,对照组患者采用饮食疗法配合使用乳果糖口服;治疗1组在对照组的基础上加用双歧杆菌乳杆菌三联活菌片(剂量为:4片/次,3次/日);治疗2组同样在对照组的基础上加用双歧杆菌乳杆菌三联活菌片(剂量为:8片/次,3次/日),比较3组患者临床疗效与用药安全性。结果:治疗2组临床治疗有效率(93.33%)高于治疗1组(73.33%),治疗1组治疗有效率高于对照组(46.67%),差异有统计学意义(P<0.05);治疗后治疗2组大便性状评分与排便费力情况评分低于治疗1组,治疗1组评分低于对照组,差异有统计学意义(P<0.05);治疗后治疗2组腹胀、腹痛、食欲不振评分低于治疗1组,治疗1组症状评分低于对照组,差异有统计学意义(P<0.05);3组患者用药安全性比较差异无统计学意义(P>0.05)。结论:大剂量双歧杆菌乳杆菌三联活菌片联合乳果糖治疗功能性便秘,可有效改善患者临床症状,疗效显著,用药安全性较高。

Objective: To explore the effects of different doses of bifidobacterium-lactobacillus triple viable tablets combined with lactulose in the treatment of functional constipation. Methods: 90 cases of functional constipation in a hospital were selected and randomly divided into treatment group 1, treatment group 2 and a control group, with 30 cases in each. The control group was given diet therapy combined with oral lactulose, treatment group 1 was added with bifidobacterium-lactobacillus triple viable tablets on the basis of the control group (dose: 4 tablets/time, 3 times/d), and treatment group 2 was added with bifidobacterium-lactobacillus triple viable tablets on the basis of the control group (dose: 8 tablets/time, 3 times/d). Clinical efficacy and medication safety were compared among the three groups. Results: The effective rate of clinical treatment in treatment group 2 was higher than that of the treatment group 1 (93.33% vs 73.33%), and the effective rate in treatment group 1 was higher than that in the control group (73.33% vs 46.67%)( P <0.05).The scores of stool property and difficult defecation after treatment in treatment group 2 were lower than those in treatment group 1, and the scores in treatment group 1 were lower than those in the control group ( P <0.05). After treatment, the scores of abdominal distension, abdominal pain and loss of appetite in treatment group 2 were lower than those in treatment group 1, and the symptom scores in treatment group 1 were lower than those in the control group ( P <0.05). There was no significant difference in terms of the medication safety among the three groups ( P >0.05). Conclusion: High-dose bifidobacterium-lactobacillus triple viable tablets combined with lactulose can effectively improve the clinical symptoms of patients with functional constipation, and it has remarkable efficacy and high medication safety.